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Introduction
Subarachnoid hemorrhage (SAH) is one of the most dev-
astating cerebrovascular diseases with high morbidity and 
mortality, and often results in long lasting neurological dis-
ability for survivors [1]. Despite the advances in neuroin-
tensive care, the underlying mechanisms of SAH-induced 
secondary brain injury are still incompletely understood. 
During the past decades, research efforts have been cen-
tered around vasospasm which is considered to be the most 
important factor for delayed neurological deficit [2, 3]. 
However the long lasting failure of anti-vasospastic treat-
ments to improve outcome of SAH in most clinical tri-
als [4] has brought into focus the significance of a more 
recently found pathological phenomenon which named 
early brain injury (EBI) [5]. EBI refers to the global brain 
injury which starts immediately after SAH and lasts 72 h 
until the development of vasospasm [6, 7]. Evidences sug-
gest that SAH-induced EBI is not only responsible for the 
initial signs and symptoms on admission, but also blamed 
for the delayed neurological deterioration which is associ-
ated with vasospasm and poor long-term prognosis [8, 9]. 
The underlying pathophysiological mechanisms of EBI 
after SAH are not definitely clarified to date. It is generally 
accepted that neuroinflammation plays a critical role in the 
happening and progressing of EBI after SAH [10–12].
Microglial cell is the resident macrophage of the cen-
tral nervous system (CNS). After SAH, especially in acute 
stage, activated microglias provoke excessive secretion of 
pro-inflammatory cytokines contributing to the develop-
ment of brain edema, disruption of blood–brain barrier 
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(BBB), and secondary neuronal injury after SAH [5]. The 
pro-inflammatory cytokines secreted by activated micro-
glial cells include interleukin-6 (IL-6), interleukin-1 beta 
(IL-1β) and tumor necrosis factor alpha (TNF-α) [13] all of 
which have been found to be increased early after SAH and 
strongly linked to the brain injury in both patients and ani-
mals [14–16]. Thus, modulating the inflammatory cytokine 
secretion of activated microglial cells might be a potential 
strategy for the treatment of EBI after SAH.
The lipid signaling molecule prostaglandin E2 (PGE2), 
which is one of the most typical downstream products 
of arachidonic acid (AA) by cyclooxygenases-1 and 2 
(COX-1 and 2), is a well-established modulator of inflam-
matory responses in a variety of CNS and peripheral injury 
models [17]. PGE2 modulates inflammatory responses 
through activating four distinct G protein-coupled recep-
tors (GPCRs) named E prostanoid 1–4 receptors (EP 1–4 
receptors), which exhibit divergent cellular expression pro-
files, desensitization kinetics and signaling cascades [18, 
19]. Among them the EP4 receptor is emerging as the most 
promising and versatile one and the effects of anti-thrombo-
sis, anti-inflammation and vasodilation have been proposed 
for it [20]. In  vivo and in  vitro studies have proved that 
activation of EP4 receptor by exogenous EP4 selective ago-
nist suppresses microglial inflammatory response to Aβ42 
peptides and lipopolysaccharide while conditional deletion 
of microglial EP4 conversely increases inflammatory gene 
expression [21, 22]. A broad variety of experimental neu-
ropathological models associated with inflammation are 
also alleviated by the activation of EP4 receptor, including 
cerebral ischemia [23, 24], hypoxic-ischemic encephalopa-
thy (HIE) [25], neurotoxicity induced brain injury [26] and 
Alzheimer’s disease [21].
The roles of EP4 receptor in EBI after SAH are currently 
unknown. Based on these prominent studies, it is reason-
able to deduce that the activation of EP4 receptor might 
suppress microglial activation as well as microglia-induced 
neuroinflammation and thus play a protectional role in EBI 
after SAH.
In this study, we investigated the effects of EP4 receptor 
activation on the microglial activation, neuroinflammation 
and EBI after SAH by selectively using EP4 receptor spe-
cific agonist or antagonist in a rat model.
Materials and Methods
Animals
Experimental animal was male Sprague–Dawley rats 
(280–350  g), afforded by animal experimental center of 
Zhejiang Chinese Medicine University. The use and care 
of animals employed in our model were approved by the 
Animal Care and Use Committee of Zhejiang Chinese 
Medicine University, in accordance with all relevant laws 
of China.
All animals were kept in a room with controlled tem-
perature of 23 ± 1 °C at 12-h dark/light cycle and fed with 
standard food and water ad libitum.
Rat Model of SAH
An endovascular perforation method was used to produce 
the model of experimental SAH according to previous stud-
ies [27, 28]. Briefly, after anesthetizing with the mixture 
of 3% isoflurane in 70%/30% medical air/oxygen, the right 
external carotid artery was transected distally and then 
reflected caudally in line with the internal carotid artery. 
A blunted monofilament nylon suture of 4-0 was inserted 
into the right external carotid artery stump and then care-
fully advanced into the internal carotid artery until a resist-
ance was felt, approximately 20–24 mm from the common 
carotid artery bifurcation. The suture was advanced for 
another 3 mm to perforate the right internal carotid artery 
close to the bifurcation with the middle cerebral artery to 
produce SAH. Sham-operated animals were suffered the 
similar procedures except the arterial perforation.
After operation, the rats were returned to their cages 
with the room temperature kept at 23 ± 1 °C. Physical cool-
ing (ice bag) was used to keep the rectal temperature at 
37 ± 0.5 °C when required.
Drug Administration
The EP4 receptor selective agonist AE1-329 and antago-
nist AE3-208 were from Ono Pharmaceuticals Co (Japan). 
Their specificity for the EP4 receptor has been proved pre-
viously [29, 30]. AE1-329 (0.3 mg/kg) was subcutaneously 
injected (SC) [23]. In several models of cerebral diseases, 
AE3-208 is administrated per os to reach an effective con-
centration in brains [31, 32]. Based on these studies, we 
administrated AE3-208 (0.3 mg/kg) subcutaneously. AE1-
329 and AE3-208 were dissolved in a solution consisting 
of 5% N-methyl pyrrolidone (NMP) and 5% solutol HS in 
saline, and each rat was subcutaneously injected with 2 ml/
kg AE1-329, AE3-208 or vehicle (5% N-methyl pyrro-
lidone (NMP) and 5% solutol HS in saline).
All drugs were administrated immediately after SAH 
and were repeated 12 h post SAH with the same dose.
Assessment of SAH Grade, Mortality and Neurological 
Score
The methods of SAH grade [33] and neurological score 
[34, 35] evaluation were described by previous studies and 
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all evaluations were performed by an experimenter blinded 
to this study.
Twenty-four hours after SAH, rats were sacrificed after 
anesthetization and brains were removed immediately for 
the measurement of SAH grades. SAH grade was evalu-
ated according to the amount of subarachnoid blood clots 
distributed in the six segments of basal cistern: grade one 
(scores = 0), no observable subarachnoid blood clots; grade 
two (scores = 1), minimal subarachnoid blood clots; grade 
three (scores = 2), moderate subarachnoid blood clots with 
recognizable arteries; and grade four (scores = 3), suba-
rachnoid blood clots covering all arteries. Possible scores 
ranged from 0 to 18 were calculated by the total scores 
from all six segments. The animal’s neurological deficits 
were evaluated by six aspects: spontaneous activity (scores 
ranged from 0 to 3), reaction to side stroking (scores ranged 
from 1 to 3), vibrissae touch (scores ranged from 1 to 3), 
forepaw outstretching (scores ranged from 0 to 3), climbing 
(scores ranged from 0 to 3), limb symmetry (scores ranged 
from 0 to 3), and beam walking ability which refers to the 
walking distances on a wooden beam for 1  min (scores 
ranged from 0 to 4). The minimum score of neurological 
deficits was 2 and the maximum was 22; a higher score rep-
resent better neurological performance. Mortality was cal-
culated at the same time.
Assessment of Brain Edema
Twenty-four hours after SAH, rats were sacrificed after 
anesthetization and entire brains were removed imme-
diately for the measurement of water content [36]. Water 
content of brain was determined by the formula (wet 
weight − dry weight)/(wet weight) × 100%. The wet weight 
of brains was obtained by the weight of freshly removed 
brains, then the wet brains were kept in an oven for 72 h at 
100 °C and weighed to obtain dry weight.
Blood Brain Barrier Permeability
BBB permeability was determined by Evans blue (EB) 
extravasation 24  h after SAH. Briefly, 2% Evans blue 
dye was injected in 2 min into the right femoral vein at a 
dose of 2 ml/kg, allowing the dye to circulate for a total of 
60  min [37]. Animals were re-anesthetized and subjected 
to transcardial perfusion with phosphate buffered saline 
(PBS) to remove intravascular EB dye, then entire brains 
were removed and homogenized in phosphate buffered 
saline. Trichloroacetic acid was then added to precipitate 
protein. After overnight incubation at 4 °C, samples were 
centrifuged and the resulting supernatants were measured 
for absorbance of EB at 620 nm using a spectrophotometer.
TUNEL Staining
Twenty-four hours after SAH, rats were anesthetized and 
perfused transcardially with 4% paraformaldehyde. Brains 
were separated and fixed in 4% paraformaldehyde for 24 h 
and dehydrated with gradient sucrose solution. Consecu-
tive coronal sections of 10 μm were cut from bregma with 
200 μm intervals. A total of 8 sections in right hemisphere 
of brain (perforation side) were obtained for terminal 
deoxynucleotidyl transferase-mediated dUTP-biotin nick 
end labeling (TUNEL) staining (Roche Diagnostics, Man-
nheim, Germany). DAPI staining was performed accord-
ing to the instructions. The images were viewed with an 
EVOS-fl digital inverted fluorescent microscopy and five 
non-overlapped vision fields were randomly chosen for 
observation in each section. The number of TUNEL posi-
tive cells was counted with Image Pro Plus 6.0 Software 
(MediaCybernetics, Bethesda, USA). The mean number of 
TUNEL/ DAPI double positive nuclei in the five views was 
taken for the apoptotic index of each section and the apop-
totic index for each animal was calculated by the final aver-
age percentage of double positive cells of the 8 sections.
Western Blot
The cortex and cerebral microvessels of right hemisphere 
were separated for western blot analysis. Samples were 
incubated with protease inhibitor (Roche) then diluted 
with sample buffer. Samples were supplemented with 
2% beta-mercaptoethanol and 50  mM DTT and boiled 
for about 5  min. Proteins were separated on tris-glycine 
4–15% acrylamide gels and transferred to PVDF mem-
branes soaked in 5% nonfat milk in PBS-Tween 20 (0.05%) 
for 2 h. The proteins of total caspase-3, cleaved caspase-3, 
Ser1177 phosphorylated endothelial nitric oxide synthase 
(Ser1177 p-eNOS) and β-actin were tested by rabbit mono-
clonal antibody against caspase-3 (Santa Cruz, 1:500), rab-
bit polyclonal antibody against cleaved caspase-3 (Biorbyt, 
1:500), rabbit polyclonal antibody against Ser1177 p-eNOS 
(Invitrogen, 1:400) and rabbit polyclonal antibody against 
β-actin (Santa Cruz, 1:500) respectively. Immunoreactiv-
ity was tested by incubation with secondary HRP-coupled 
antibody for 1 h at room temperature followed by the ECL 
plus reagent (Santa Cruz). The densities of the bands were 
determined by the MiVnt image analysis system (Bio-Rad, 
Carlsbad, CA, USA).
Immunofluorescence Staining
Consecutive coronal sections of 10  μm were cut from 
bregma with 200  μm intervals. A total of eight sections 
in right hemisphere (perforation side) were obtained for 
immunofluorescence staining. The sections were incubated 
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with rabbit polyclonal antibody against Iba-1 (Santa Cruz, 
1:300) at 4 °C overnight, then followed by incubating with 
Dylight 488-conjugated goat anti-rabbit antibody (Jack-
son ImmunoResearch, 1:1000). DAPI was used for nuclear 
staining. Sections viewed under the confocal microscope 
(Nikon). The number of Iba-1 positive cells was counted 
with Image Pro Plus 6.0 Software (MediaCybernetics, 
Bethesda, USA).
Enzyme Linked Immunosorbent Assay
The right hemisphere of brain was separated for the deter-
mining of the levels of inflammatory factors by a ELISA 
kits according to the instructions (TNF-α from Diaclone 
Research, Besancon, France; IL-1β, IL-6 from BioSource 
Europe SA, Nivelles, Belgium).
Quantitative Real‑Time Polymerase Chain Reaction 
(RT‑qPCR)
The quantification of mRNA levels of inflammatory fac-
tors was performed by RT-qPCR as previously described 
[38]. The right hemisphere of brain (perforation side) was 
obtained at 24  h after SAH and total RNA from the cor-
tex was isolated using TRIzol (Invitrogen, USA) with the 
PureLink RNA Mini Kit (Invitrogen, USA) as instructions. 
The purity and concentration of RNA were tested by spec-
trophotometric analysis (OD 260/280) and agarose gel elec-
trophoresis. Then RNA was reverse-transcribed to obtain 
cDNA using SuperScript II Reverse Transcriptase (Invitro-
gen, USA). The reaction was ended by heating at 70 °C for 
10 min. RT-qPCR was performed using the CFX96 Real-
time PCR detection system (Bio-Rad, USA), applying real-
time SYBR Green PCR technology. The reaction mixtures 
(25  μl) contained 12.5  μl SYBR Green, 9.5  μl nuclease-
free water, 1 μl cDNA, 1 μl forward primer (10 μM) and 
1 μl reverse primer (10 μM). The primers sequences were 
designed by the Genscript Biological Technology Com-
pany (Nanjing, China) according to the gene sequences 
reported in GenBank. The IL-1β primers were 50′ -CAC 
CTC TCA AGC AGA GCA CAG-30′ (forward) and 50′-GGG 
TTC CAT GGT GAA GTC AAC-30′ (reverse). The IL-6 
primers were 50′-TCC TAC CCC AAC TTC CAA TGCTC-30′ 
(forward) and 50′-TTG GAT GGT CTT GGT CCT TAGCC-
30′ (reverse). The TNF-α primer were 50′-AAA TGG GCT 
CCC TCT CAT CAG TTC -30′ (forward) and 50′-TCT GCT 
TGG TGG TTT GCT ACGAC-30′ (reverse). The GAPDH 
primers were 5′-ACA GCA ACA GGG TGG TGG AC-3′ (for-
ward) and 5′-TTT GAG GGT GCA GCG AAC TT-3′ (reverse). 
After 95 °C for 1 min, 40 cycles were performed and each 
cycle contained a denaturation step at 95 °C for 15 s and an 
annealing step at 60 °C for 1 min. The melting curve which 
was measured immediately after amplification, showed a 
single product peak indicating the good product specificity. 
All samples were analyzed in triplicate. Data were analyzed 
using the Line-Gene software. The mRNA expression lev-
els were calculated with the 2-ΔΔCq method and normal-
ized by quantity of GAPDH mRNA.
Statistic Analysis
All data were presented as means ± standard error of the 
mean (SEM) and SPSS 12.0 was used for statistical analy-
sis of the results. Data were subjected to one-way analysis 
of variance (ANOVA) followed by the LSD and Dunnett’s 
post-hoc test for multiple comparisons. The difference of 
mortality rate was analyzed by Chi square test. A value of 
p < 0.05 was considered as statistical significance.
Results
Effects of EP4 Receptor on SAH Grade, Mortality 
and Neurological Score
Twenty-four hours after SAH, the SAH grade of SAH 
group treated with vehicle (14.4 ± 1.41) did not signifi-
cantly differ from those of treated with EP4 receptor spe-
cific agonist AE1-329 (13.8 ± 1.36) or antagonist AE3-208 
(14.1 ± 1.38), suggesting the modulation of EP4 receptor 
by AE1-329 or AE3-208 did not affect the bleeding levels 
(Fig. 1b).
There are no animals of sham group died after surgery. 
The mortality of the SAH treated with vehicle was 32.1% 
(9 of 28 rats). The mortality of the SAH treated with AE1-
329 and AE3-208 was 21.4% (6 of 28 rats) and 39.3% (11 
of 28 rats) respectively (Fig. 1c).
The neurological score was significantly decreased in 
the SAH group treated with vehicle (12.8 ± 1.3) compared 
with the sham group (20.8 ± 1.5). AE1-329 administration 
increased neurological score (16.3 ± 1.6) compared with 
SAH treated with vehicle, while AE3-208 showed opposite 
effects (9.2 ± 0.9) (Fig. 1d).
Effects of EP4 Receptor on Brain Edema and BBB 
Permeability After SAH
Twenty-four hours after SAH, brain water content of 
SAH group treated with vehicle (81.47 ± 0.22%) was 
significantly increased compared with sham group 
(78.77 ± 0.21%). AE1-329 decreased brain water content 
(80.25 ± 0.22%) while AE3-208 increased the brain water 
content (82.63 ± 0.23%) (Fig.  2a). Rats of SAH group 
treated with vehicle showed a significant increase in BBB 
permeability to Evans blue (19.9  ng/mg protein) indicat-
ing an early damage of BBB after SAH. AE1-329 improved 
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the BBB damage as demonstrated by the decrease of Evans 
blue extravasation (15.6  ng/mg protein) while AE3-208 
showed opposite effects (23.8 ng/mg protein) (Fig. 2b).
Effects of EP4 Receptor on Neuronal Apoptosis After 
SAH
Twenty-four hours post SAH, about 5.64 ± 0.51% cells of 
SAH group treated with vehicle showed apoptosis (Fig. 4a, 
b). AE1-329 significantly mitigated cellular apoptosis 
(3.12 ± 0.29%) while AE3-208 aggravated cellular apopto-
sis (9.39 ± 0.97%) (Fig.  3a, b). The expression of cleaved 
caspase-3 in SHA group also increased dramatically 
compared with that of sham group, which was downregu-
lated by AE1-329 and upregulated by AE3-208 (Fig. 3c).
Effects of EP4 Receptor on the Activation of Microglia 
After SAH
After SAH, microglia transform from the resting sta-
tus to highly activated status. The hallmarks of activated 
microglia include morphological changes, production of 
pro-inflammatory cytokines and enhanced proliferation 
[39–41].
In sham group, the density of Iba-1 positive cells was 
24.3 ± 2.47/mm2. Twenty-four hours post SAH, the micro-
glias in SAH treated with vehicle group increased in 
Fig. 1  Effects of EP4 receptor on SAH grade, mortality and neu-
rological score 24  h after SAH. Representative images showed rat 
brains of sham and SAH groups (a). EP4 modulation did not affect 
the SAH grade (n = 12) (b). The activation of EP4 by AE1-329 
decreased mortality (n = 28) and attenuated neurological deficits 
(n = 12) 24  h after SAH while the inhibition of EP4 by AE3-208 
showed opposite effects (c, d). Data were expressed as mean ± SEM 
(###p < 0.001 vs. Sham, * p< 0.05 vs. SAH treated with vehicle, 
**p < 0.01 vs. SAH treated with vehicle)
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number (186.5 ± 10.7/mm2) and became activated, altering 
their morphology with upregulation of Iba-1 (Fig.  4a, b). 
AE1-329 significantly attenuated Iba-1 positive microglia 
number (105.8 ± 8.5/mm2) and  it’s activation, while AE3-
208 showed opposite effects (225.5 ± 12.4/mm2) (Fig.  4a, 
b).
Effects of EP4 Receptor on the Levels of Inflammatory 
Cytokines After SAH
To further explore the effects of EP4 receptor activation on 
the neuroinflammation after SAH, we measured the mRNA 
and protein levels of pro-inflammatory cytokines TNF-a, 
IL-1β and IL-6 in the cortex at 24 h after injury. RT-qPCR 
analysis showed AE1-329 reduced the mRNA expression 
of TNF-a, IL-1β and IL-6 while AE3-208 increased the 
mRNA expression (Fig. 5a, c, e).
Enzyme linked immunosorbent assay showed, com-
pared with the sham group (5.9 ± 0.27  ng/g in TNF-
α, 22.1 ± 1.1  ng/g in IL-1β and 42.8 ± 2.2  ng/g in IL-6 
respectively), the levels of inflammatory cytokines sig-
nificantly increased in the SAH treated with vehicle group 
(16.9 ± 0.85  ng/g in TNF-α, 57.0 ± 2.3  ng/g in IL-1β and 
81.4 ± 3.9 ng/g in IL-6 respectively) 24 h after SAH. AE1-
329 downregulated the levels of inflammatory cytokines 
(12.1 ± 0.54  ng/g in TNF-α, 39.7 ± 1.9  ng/g in IL-1β 
and 63.7 ± 3.5  ng/g in IL-6 respectively) while AE3-
208 showed opposite effects (21.3 ± 1.1  ng/g in TNF-α, 
73.4 ± 4.1 ng/g in IL-1β and 94.5 ± 4.6 ng/g in IL-6 respec-
tively) (Fig. 5b, d, f).
Effects of EP4 Receptor on the Expression of p‑eNOS
Western blot analysis showed Ser1177 p-eNOS expres-
sion increased 24 h after SAH (2.70 folds higher than sham 
group) (Fig. 6a, b). Compared with SAH treated with vehi-
cle group, AE1-329 increased the expression of Ser1177 
p-eNOS (3.94 folds higher than sham group) and AE3-
208 showed opposite effects (1.74 folds higher than sham 
group) (Fig. 6a, b).
Discussion
In this study we present the neuroprotective effects induced 
by EP4 receptor activation on EBI after SAH. Our results 
showed that the activation of EP4 by AE1-329 signifi-
cantly improved neurological dysfunctions, reduced mor-
tality, attenuated brain edema and BBB damage 24 h after 
SAH. In addition, EP4 activation downregulated the micro-
glial activation, reduced the pro-inflammatory cytokine 
concentrations such as TNF-α, IL-1β and IL-6 in cortex 
and increased the Ser1177 p-eNOS expression 24  h after 
SAH. Moreover, EP4 activation decreased the number 
of TUNEL-positive cells and active caspase-3 in cortex 
24 h after SAH. These findings suggested that EP4 activa-
tion protected brain from SAH-induced EBI. The contrary 
effects induced by EP4 specific antagonist AE3-208 further 
contributed to determine the roles of EP4 in EBI after SAH.
The pathophysiologic mechanisms related to EBI are 
under investigating. Increased intracranial pressure (ICP), 
reduced cerebral blood flow (CBF) and cerebral perfusion 
Fig. 2  Effects of EP4 receptor on brain edema and BBB permeability 
after SAH. The activation of EP4 by AE1-329 decreased brain water 
content and BBB permeability to Evans blue 24 h after SAH while 
the inhibition of EP4 by AE3-208 showed opposite effects (a, b). 
Data were expressed as mean ± SEM (n = 12, ###p < 0.001 vs. Sham, 
*p < 0.05 vs. SAH treated with vehicle, **p < 0.01 vs. SAH treated 
with vehicle)
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pressure (CPP), BBB damage, brain edema, brain swell-
ing and dysfunction of autoregulation, all of which stem 
from the initial bleeding in SAH, constitute the patho-
physiological variables occurring at the EBI period [42]. 
Among them, the most immediate event following SAH 
is an arrest in intracranial circulation caused by a peak of 
ICP which can reach to the level of mean arterial blood 
pressure shortly after SAH [43]. This temporary circula-
tory arrest results in a hypoxic state which leads to the 
apoptosis of neurons and glias due to the energy failure, 
and initiates the cascade of events leading to cytotoxic 
edema [42]. Ischemia also causes apoptosis of cells that 
constitute the BBB, which results in the increased diffu-
sion of serum from the vascular lumen into cerebral tis-
sues and eventually the vasogenic edema [44]. SAH also 
activates astrocytes and microglias, and upregulates the 
production and secretion of pro-inflammatory cytokines 
[45, 46]. Pro-inflammatory cytokines enhance brain 
Fig. 3  Effects of EP4 receptor on neuronal apoptosis after SAH. 
TUNEL study showed the activation of EP4 by AE1-329 attenu-
ated neuronal apoptosis 24 h after SAH while the inhibition of EP4 
by AE3-208 showed opposite effects (a, b). Western blot analy-
sis showed AE1-329 decreased the expression of cleaved caspase-3 
24  h after SAH and AE3-208 showed opposite effects (c). Nuclear 
morphology was indicated by DAPI staining and DNA breaks were 
detected by TUNEL analyses. Bar: 25  µm. Data were expressed as 
mean ± SEM (n = 8, ###p < 0.001 vs. Sham, *p < 0.05 vs. SAH treated 
with vehicle, ***p < 0.001 vs. SAH treated with vehicle)
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edema through the disrupting of BBB and induce neu-
ronal apoptosis, and therefore directly contribute to early 
brain damage [10, 47].
Our data indicated that the activation of EP4 receptor by 
AE1-329 improved brain edema, BBB damage and neuro-
logical outcomes. These results are consistent with some 
previous studies demonstrating that the activation of EP4 
receptor shows neuroprotective effects on other CNS insults 
such as cerebral ischemia [23, 24], hypoxic-ischemic 
encephalopathy (HIE) [25], neurotoxicity induced brain 
injury [26] and  Alzheimer’s disease [21].
The mechanisms underlying these EP4-induced neu-
roprotective effects were complicated and multiple cell 
types, including microglias, neurons and endothelial cells 
might be involved. Our findings indicated that the phar-
macologic activation of EP4 receptor elicited the down-
regulation of microglial activity, the mRNA and protein 
expression of inflammatory cytokines. The production 
Fig. 4  Effects of EP4 receptor on the activation of microglia after 
SAH. Iba-1 staining for microglias showed activation of EP4 by AE1-
329 attenuated the number and activation of microglias in the brain 
24 h after SAH while inhibition of EP4 by AE3-208 showed opposite 
effects (a, b). Microglia was indicated by Iba-1 staining and nuclear 
was indicated by DAPI staining. Bar: 25 µm. Data were expressed as 
mean ± SEM (n = 8, ###p < 0.001 vs. Sham, *p < 0.05 vs. SAH treated 
with vehicle,***p < 0.001 vs. SAH treated with vehicle)
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Fig. 5  Effects of EP4 receptor on the levels of inflammatory 
cytokines after SAH. RT-qPCR analysis showed EP4 activation by 
AE1-329 reduced the mRNA expression of TNF-a IL-1β and IL-6 
while inhibition of EP4 by AE3-208 increased the mRNA expres-
sion (a, c, e). Enzyme linked immunosorbent assay showed activation 
of EP4 by AE1-329 attenuated the levels of inflammatory cytokines 
while inhibition of EP4 by AE3-208 showed opposite effects (b, d, 
f). Data were expressed as mean ± SEM (n = 8, ###p < 0.001 vs. Sham, 
*p < 0.05 vs. SAH treated with vehicle, **p < 0.01 vs. SAH treated 
with vehicle, ***p < 0.001 vs. SAH treated with vehicle)
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of pro-inflammatory cytokines is one of the hallmarks of 
microglial activation. In our study, we did not explored 
how SAH-induced production of TNF-a IL-1β and IL-6 
was regulated by EP4 receptor. The suppression of micro-
glial activation might account for the reduction of the 
pro-inflammatory cytokines. Going further, the activa-
tion of nuclear factor-kappaB (NF-κB) is required for the 
generating of TNF-a, IL-1β and IL-6 in microglia [48]. 
Woodling et  al. have found that EP4 signaling broadly 
represses the activation of target genes for interferon 
regulatory factors (IRFs) and NF-κB, which are central 
transcription factors regulating the microglial response 
to Aβ42 stimulation [21]. The similar NF-κB suppression 
after EP4 activation has also been reported by Shi et al. 
in a brain innate immunity model induced by lipopoly-
saccharide (LPS) [22].
In addition to anti-inflammatory effects, we also found 
the selective activation of EP4 significantly decreased the 
number of TUNEL positive cells and level of active cas-
pase-3 after SAH. This should not be entirely ascribed to 
the suppression of neuroinflammatory reaction after EP4 
activation, as EP4 receptors also locate on neurons and 
their activation by AE1-329 have shown a neuroprotective 
effect on brain ischemia [23].
We also found the upregulation of Ser1177 p-eNOS 
expression after AE1-329 administration. The endothelial 
EP4 receptor which expresses at a very low level in nor-
mal condition markedly upregulates in vasculature under 
the stimulation of ischemia and systemical administration 
of AE1-329 greatly elevate protein levels of eNOS and acti-
vated phospho-Ser1177 eNOS in mouse cerebral microves-
sels [23]. The activation of eNOS and increased NO pro-
duction result in cGMP dependent smooth muscle cell 
relaxation and increased cerebral blood flow [49]. Endothe-
lial EP4 activation by AE1-329 might directly inhibit the 
increase in BBB permeability in mouse experimental auto-
immune encephalomyelitis [31].
Another neuroprotective mechanism initiated by EP4 
activation in this study might involve the peripheral inflam-
matory cells including neutrophils, macrophages and lym-
phocytes. Transmission of inflammatory cells from periph-
ery blood to CNS has been demonstrated in the clinical 
and animal studies of SAH, which can result in not only 
the neuroinflammatory aggravation but also the early neu-
ronal loss and BBB damage [50, 51]. Peripheral adminis-
tration of the EP4 specific agonist AE1-329 downregulates 
the secreted levels of pro-inflammatory cytokines and 
chemokines from macrophages and neutrophils [22, 52].
Taken together, in present study, EP4 activation appears 
to have a multiple beneficial properties for EBI after SAH. 
However, the precise mechanisms of the neuroprotective 
effects of EP4 activation on EBI after SAH remain unclear 
and further studies exploring the underlying mechanisms of 
EP4 are required in future.
Conclusion
This study is the first one to explore the effects of EP4 
receptor activation on EBI after experimental SAH. We 
find the activation of EP4 receptor by AE1-329 improves 
neurological dysfunctions, and ameliorates brain edema 
and BBB damages after SAH. Meanwhile activation of 
EP4 receptor suppresses microglial activation, the protein 
and mRNA levels of pro-inflammatory cytokines TNF-a, 
IL-1β and IL-6 and increases Ser1177 p-eNOS expression. 
Furthermore, activation of EP4 receptor attenuates cellular 
apoptosis through downregulating active caspase-3. Our 
results suggest EP4 receptor may be a promising potential 
target for SAH therapy.
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Fig. 6  Effects of EP4 receptor 
on the expression of p-eNOS. 
Western blot analysis showed 
AE1-329 increased the expres-
sion of Ser1177 p-eNOS 24 h 
after SAH and AE3-208 showed 
opposite effects (a, b). Data 
were expressed as mean ± SEM 
(n = 8, ###p < 0.001 vs. Sham, 
*p < 0.05 vs. SAH treated with 
vehicle, **p < 0.01 vs. SAH 
treated with vehicle)
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